Bicocca Open Archive

Logo unimib boa
CAZZANIGA, GIOVANNI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 30.795
AS - Asia 17.121
EU - Europa 13.463
SA - Sud America 2.558
AF - Africa 397
OC - Oceania 35
Continente sconosciuto - Info sul continente non disponibili 24
Totale 64.393
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 29.011
SG - Singapore 6.031
IT - Italia 3.685
CN - Cina 3.430
HK - Hong Kong 2.501
VN - Vietnam 2.425
RU - Federazione Russa 2.048
BR - Brasile 1.895
CA - Canada 1.545
DE - Germania 1.396
IE - Irlanda 1.394
SE - Svezia 1.369
UA - Ucraina 782
GB - Regno Unito 642
FR - Francia 595
BD - Bangladesh 534
IN - India 468
FI - Finlandia 368
AT - Austria 247
AR - Argentina 245
ID - Indonesia 238
KR - Corea 219
TR - Turchia 216
NL - Olanda 191
ES - Italia 185
IQ - Iraq 185
PK - Pakistan 141
MX - Messico 140
JP - Giappone 133
ZA - Sudafrica 121
SA - Arabia Saudita 110
PL - Polonia 108
EC - Ecuador 97
CO - Colombia 82
DK - Danimarca 78
PH - Filippine 78
VE - Venezuela 76
BE - Belgio 68
CH - Svizzera 68
UZ - Uzbekistan 59
PY - Paraguay 44
EG - Egitto 43
CL - Cile 42
MA - Marocco 42
CZ - Repubblica Ceca 40
MY - Malesia 39
JO - Giordania 37
KE - Kenya 37
PE - Perù 33
TN - Tunisia 31
AE - Emirati Arabi Uniti 30
ET - Etiopia 30
GR - Grecia 28
IL - Israele 27
AU - Australia 26
KZ - Kazakistan 24
PT - Portogallo 24
AZ - Azerbaigian 22
BG - Bulgaria 22
NP - Nepal 22
JM - Giamaica 21
LB - Libano 21
LT - Lituania 21
UY - Uruguay 21
DZ - Algeria 20
TW - Taiwan 17
EU - Europa 16
IR - Iran 16
OM - Oman 16
RO - Romania 16
TH - Thailandia 16
BO - Bolivia 15
CR - Costa Rica 15
AL - Albania 14
PA - Panama 12
SN - Senegal 12
DO - Repubblica Dominicana 11
NO - Norvegia 11
AO - Angola 10
HR - Croazia 9
KG - Kirghizistan 9
NG - Nigeria 9
NI - Nicaragua 9
TT - Trinidad e Tobago 9
BH - Bahrain 8
HU - Ungheria 8
MU - Mauritius 8
RS - Serbia 8
BY - Bielorussia 7
SY - Repubblica araba siriana 7
KW - Kuwait 6
LV - Lettonia 6
NZ - Nuova Zelanda 6
SK - Slovacchia (Repubblica Slovacca) 6
EE - Estonia 5
GE - Georgia 5
LK - Sri Lanka 5
LY - Libia 5
QA - Qatar 5
RE - Reunion 5
Totale 64.293
Salva come PNG Salva come JPEG
Città #
Ann Arbor 3.634
Singapore 3.496
Ashburn 2.697
Hong Kong 2.448
Fairfield 2.293
Woodbridge 2.114
Houston 1.684
San Jose 1.381
Dublin 1.360
Chandler 1.252
Toronto 1.200
Milan 1.090
Wilmington 1.068
Seattle 894
Frankfurt am Main 850
Cambridge 799
New York 766
Jacksonville 760
Ho Chi Minh City 744
Santa Clara 607
Dearborn 605
Hanoi 531
Los Angeles 520
Chicago 515
Beijing 514
Princeton 493
The Dalles 400
Hefei 374
Dallas 366
Lauterbourg 257
Lawrence 239
Nanjing 233
Altamura 224
Moscow 216
Shanghai 215
Rome 214
Buffalo 206
Seoul 202
Vienna 188
São Paulo 180
Council Bluffs 168
Jakarta 167
Boardman 160
San Diego 156
Helsinki 152
Lachine 124
Orem 112
Munich 111
Guangzhou 98
London 94
Warsaw 89
Montreal 88
Nuremberg 88
Tokyo 85
Denver 83
Lissone 81
Dong Ket 80
Nanchang 80
Andover 79
Brooklyn 77
Da Nang 76
Haiphong 76
Baghdad 75
Shenyang 67
Chennai 65
Tianjin 65
Changsha 64
Rio de Janeiro 63
Fuzhou 62
Phoenix 62
Brussels 61
Salt Lake City 60
Turin 56
Hebei 55
Jinan 53
Zurich 53
Paris 52
Stockholm 52
Atlanta 51
Johannesburg 49
Poplar 49
Tashkent 48
Naples 45
Amsterdam 44
Biên Hòa 43
Hải Dương 43
San Francisco 43
Turku 43
Lappeenranta 41
Norwalk 41
Zhengzhou 41
Bologna 40
Belo Horizonte 39
Jeddah 39
Dhaka 38
Ha Long 38
Brasília 37
Lahore 37
Hangzhou 36
Manchester 36
Totale 42.039
Salva come PNG Salva come JPEG
Nome #
Four Additional Doses of PEG-L-Asparaginase during the Consolidation Phase in the AIEOP-BFM ALL 2009 Protocol Do Not Improve Outcome and Increase Toxicity in High-Risk ALL: Results of a Randomized Study 543
BEYOND THE TUMOUR: CHILDHOOD CANCER PREDISPOSING SYNDROMES [Guardare oltre il tumore: le cancer-predisposingsyndrome in età pediatrica] 525
Prenatal Origin of Pediatric Leukemia: Lessons From Hematopoietic Development 512
Pro-inflammatory cytokines favor the emergence of ETV6-RUNX1-positive pre-leukemic cells in a model of mesenchymal niche 479
First evidence of a paediatric patient with Cornelia de Lange syndrome with acute lymphoblastic leukaemia 463
Sleeping Beauty-engineered CAR T cells achieve anti-leukemic activity without severe toxicities 455
Predictive value of minimal residual disease in philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies 454
NIPBL: a new player in myeloid cells differentiation 448
IKZF1 plus defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric b-cell precursor acute lymphoblastic leukemia 442
Clinical features and outcome of SIL/TAL1-positive t-cell acute lymphoblastic leukemia in children and adolescents: A 10-year experience of the AIEOP group 428
Hodgkin lymphoma in a patient with mosaic trisomy 18: First clinical observation 427
Preclinical Efficacy and Safety of CD19CAR Cytokine-Induced Killer Cells Transfected with Sleeping Beauty Transposon for the Treatment of Acute Lymphoblastic Leukemia 415
A simple RNA target capture NGS strategy for fusion genes assessment in the diagnostics of pediatric B-cell acute lymphoblastic leukemia 411
Biallelic PI4KA Mutations Disrupt B-Cell Metabolism and Cause B-Cell Lymphopenia and Hypogammaglobulinemia 402
First-hit SETBP1 mutations cause a myeloproliferative disorder with bone marrow fibrosis 391
Absent B cells, agammaglobulinemia, and hypertrophic cardiomyopathy in folliculin-interacting protein 1 deficiency 386
Phenotypical and Functional Characterization of Mesenchymal Stem Cells Derived From Patients Affected by Schwachman-Diamond Syndrome 385
Idiopathic erythrocytosis: a germline disease? 381
Unravelling the cellular origin and clinical prognostic markers of infant B-cell acute lymphoblastic leukemia using genome-wide analysis 378
The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL 376
Good outcome for very high risk adult B-cell acute lymphoblastic leukaemia carrying genetic abnormalities t(4;11)(q21;q23) or t(9;22)(q34;q11), if promptly submitted to allogeneic transplantation, after obtaining a good molecular remission 372
Immunogenotype changes prevail in relapses of young children with TEL-AML1-positive acute lymphoblastic leukemia and derive mainly from clonal selection 369
Hematopoietic Stem Cell (HSC)-Independent Progenitors Are Susceptible to Mll-Af9-Induced Leukemic Transformation 368
Activin A contributes to the definition of a pro-oncogenic bone marrow microenvironment in t(12;21) preleukemia 367
TNFRSF13C (BAFFR) positive blasts persist after early treatment and at relapse in childhood B-cell precursor acute lymphoblastic leukaemia 356
NG2 is a target gene of MLL-AF4 and underlies glucocorticoid resistance in MLL-r B-ALL by regulating NR3C1 expression 346
Antileukemic efficacy of BET inhibitor in a preclinical mouse model of MLL-AF4 + infant ALL 344
Cytoskeletal Regulatory Gene Expression and Migratory Properties of B Cell Progenitors are Affected by the ETV6-RUNX1 Rearrangement 335
Engineered T cells towards TNFRSF13C (BAFFR): a novel strategy to efficiently target B-cell acute lymphoblastic leukaemia 334
Optimization of PCR-based minimal residual disease diagnostics for childhood acute lymphoblastic leukemia in a multi-center setting 330
The bone marrow niche in b-cell acute lymphoblastic leukemia: The role of microenvironment from pre-leukemia to overt leukemia 330
Two siblings presenting with novel ADA2 variants, lymphoproliferation, persistence of large granular lymphocytes, and T-cell perturbations 329
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition 322
Poor prognosis for P2RY8-CRLF2 fusion but not for CRLF2 over-expression in children with intermediate risk B-cell precursor acute lymphoblastic leukemia 315
Suppressors and activators of JAK-STAT signaling at diagnosis and relapse of acute lymphoblastic leukemia in Down syndrome 315
Prognostic value of rare IKZF1 deletion in childhood B-cell precursor acute lymphoblastic leukemia: An international collaborative study 314
CEQer: A Graphical Tool for Copy Number and Allelic Imbalance Detection from Whole-Exome Sequencing Data 313
Drug-induced immunophenotypic modulation in childhood ALL: implications for minimal residual disease detection 312
Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model 311
Minimal residual disease-directed risk stratification using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the international multicenter trial AIEOP-BFM ALL 2000 for childhood acute lymphoblastic leukemia 309
CRLF2 over-expression is a poor prognostic marker in children with high risk T-cell acute lymphoblastic leukemia 307
Recurrent genetic fusions redefine MLL germ line acute lymphoblastic leukemia in infants 307
SRC/ABL inhibition disrupts CRLF2-driven signaling to induce cell death in B-cell acute lymphoblastic leukemia 305
High-throughput screening as a drug repurposing strategy for poor outcome subgroups of pediatric B-cell precursor Acute Lymphoblastic Leukemia 302
High EVI1 Expression due to NRIP1/EVI1 Fusion in Therapy-related Acute Myeloid Leukemia: Description of the First Pediatric Case 302
Efficient detection of leukemia-related fusion transcripts by multiplex PCR applied on a microelectronic platform 298
PAX5/TEL acts as a transcriptional repressor causing down-modulation of CD19, enhances migration to CXCL12, and confers survival advantage in pre-BI cells 297
Development of a quantitative-PCR method for specific FLT3/ITD monitoring in acute myeloid leukemia 295
A novel homozygous disruptive PRF1 variant (K285Sfs*4) causes very early-onset of familial hemophagocytic lymphohystiocytosis type 2 295
Clinico-biologic features of 5202 acute lymphoblastic leukemia patients enrolled in the Italian AIEOP and GIMEMA Protocols and stratified in age-cohorts 293
Standardisation and consensus guidelines for minimal residual disease assessment in Philadelphia-positive acute lymphoblastic leukemia (Ph + ALL) by real-time quantitative reverse transcriptase PCR of e1a2 BCR-ABL1 291
Characterization of children with FLT3-ITD acute myeloid leukemia: A report from the AIEOP AML-2002 study group 291
PAX5 fusion genes are frequent in poor risk childhood acute lymphoblastic leukaemia and can be targeted with BIBF1120 289
Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia 289
Predictive factors of relapse and survival in childhood acute myeloid leukemia: Role of minimal residual disease 289
Randomized post-induction and delayed intensification therapy in high-risk pediatric acute lymphoblastic leukemia: long-term results of the international AIEOP-BFM ALL 2000 trial 289
Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype 287
Donor-derived CARCIK-CD19 cells engineered with Sleeping Beauty transposon in acute lymphoblastic leukemia relapsed after allogeneic transplantation 284
Abnormal B-Cell Maturation and Increased Transitional B Cells in CBL Syndrome 282
Antibody Deficiency in Patients with Biallelic KARS1 Mutations 282
Phosphoproteomic analysis reveals hyperactivation of mTOR/STAT3 and LCK/Calcineurin axes in pediatric early T-cell precursor ALL 279
LCK over-expression drives STAT5 oncogenic signaling in PAX5 translocated BCP-ALL patients 277
PAX5/ETV6 alters the gene expression profile of precursor B cells with opposite dominant effect on endogenous PAX5 274
PTEN opposes negative selection and enables oncogenic transformation of pre-B cells 272
Minimal residual disease before and after transplantation for childhood acute lymphoblastic leukaemia: is there any room for intervention? 272
Nodal monoclonal CD5-positive B-lymphocytosis and toxoplasma lymphadenitis: Another variant in the spectrum of infectious lymphadenitis in patients with chronic leukemia/small lymphocytic lymphoma 271
Dexamethasone vs prednisone in induction treatment of pediatric ALL: results of the randomized trial AIEOP-BFM ALL 2000 271
Mesenchymal stem cells from Shwachman-Diamond syndrome patients display normal functions and do not contribute to hematological defects 269
Fine Tuning of Surface CRLF2 Expression and Its Associated Signalling Profile in Childhood B Cell Precursor Acute Lymphoblastic Leukemia 269
Clonal variegation and dynamic competition of leukemia-initiating cells in infant acute lymphoblastic leukemia with MLL rearrangement 269
Acute myeloid leukemia in Baraitser–Winter cerebrofrontofacial syndrome 268
Somatically acquired JAK1 mutations in adult acute lymphoblastic leukemia 267
Metabolic gatekeeper function of B-lymphoid transcription factors 267
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome 266
Detection of PICALM-MLLT10 (CALM-AF10) and outcome in children with T-lineage acute lymphoblastic leukemia 264
The KMT2A recombinome of acute leukemias in 2023 263
What is the relevance of Ikaros gene deletions as prognostic marker in pediatric Philadelphia negative B-cell precursor acute lymphoblastic leukemia? 263
DNA copy-number abnormalities do not occur in infant ALL with t(4;11)/MLL-AF4 262
Modeling Cornelia de Lange syndrome in vitro and in vivo reveals a role for cohesin complex in neuronal survival and differentiation 262
Germ-Line TP53 Mutation in an Adolescent With CMML/Atypical CML and Familiar Cancer Predisposition 262
Defining the correct role of minimal residual disease tests in the management of acute lymphoblastic leukaemia 261
IKZF1 Deletions with COBL Breakpoints Are Not Driven by RAG-Mediated Recombination Events in Acute Lymphoblastic Leukemia 261
Highly sensitive mutations detection in BCR-ABL positive leukemia prior and during imatinib treatment 260
Novel Chimeric Transcripts Involving PAX5 in B-Cell Precursor ALL 260
Synergistic drug interactions of the histone deacetylase inhibitor givinostat (ITF2357) in CRLF2-rearranged pediatric B-cell precursor acute lymphoblastic leukemia identified by high-throughput drug screening 259
Standardization of WT1 mRNA quantitation for minimal residual disease monitoring in childhood AML and implications of WT1 gene mutations: a European multicenter study 259
Prospective molecular monitoring of BCR/ABL transcript in children with Ph+ acute lymphoblastic leukaemia unravels differences in treatment response 259
Droplet Digital PCR Improves IG-/TR-based MRD Risk Definition in Childhood B-cell Precursor Acute Lymphoblastic Leukemia 258
Potential role of STAG1 mutations in genetic predisposition to childhood hematological malignancies 257
Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial 256
Relapses and treatment-related events contributed equally to poor prognosis in children with ABL-class fusion positive B-cell acute lymphoblastic leukemia treated according to AIEOP-BFM protocols 255
High incidence and unique features of antigen receptor gene rearrangements in TEL-AML1-positive leukemias 254
Case Report: Hypomorphic Function and Somatic Reversion in DOCK8 Deficiency in One Patient With Two Novel Variants and Sclerosing Cholangitis 253
Three novel fusion transcripts of the paired box 5 gene in B-cell precursor acute lymphoblastic leukemia 252
Exploring glioblastoma heterogeneity: the impact of ecDNA on tumor evolution and progression 251
Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study 250
Impact of IKZF1 deletions on IKZF1 expression and outcome in Philadelphia chromosome negative childhood BCP-ALL. Reply to "incidence and biological significance of IKZF1/Ikaros gene deletions in pediatric Philadelphia chromosome negative and Philadelphia chromosome positive B-cell precursor acute lymphoblastic leukemia". 250
PAX5 Fusion Genes Activate The STAT5 Signaling Pathway Through Lck Over-Expression 248
DNA variants in DHFR gene and response to treatment in children with childhood B ALL: Revisited in AIEOP-BFM protocol 248
Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study 248
Totale 31.732
Salva come PNG Salva come JPEG
Categoria #
all - tutte 213.357
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 213.357
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021403 0 0 0 0 0 0 0 0 0 0 0 403
2021/20223.278 232 342 419 237 256 271 123 177 208 230 227 556
2022/20235.119 663 1.625 374 426 282 793 67 292 332 31 154 80
2023/20244.081 119 130 173 185 528 1.087 816 152 357 85 81 368
2024/20259.831 466 1.067 552 447 866 311 662 292 1.069 1.516 861 1.722
2025/202625.289 3.009 1.663 1.751 2.696 2.926 1.262 3.118 1.250 1.825 2.067 2.045 1.677
Totale 65.622